In contrast to the findings in breast cancer, we found that enhanced expression of GSDMD in patients with hepatocellular carcinoma (HCC) did not correlate with improved overall survival, relapse-free survival or with a myeloid signature. The gene discussed is GSDMD; the disease is hepatocellular carcinoma.